Literature DB >> 21194871

Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.

David J Schneider.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 21194871     DOI: 10.1016/j.jacc.2010.11.016

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  6 in total

Review 1.  The evolution of antiplatelet therapy in cardiovascular disease.

Authors:  Omair Yousuf; Deepak L Bhatt
Journal:  Nat Rev Cardiol       Date:  2011-07-12       Impact factor: 32.419

2.  [New antiplatelet agents and the question of dual antiplatelet therapy].

Authors:  K Schrör
Journal:  Internist (Berl)       Date:  2012-03       Impact factor: 0.743

3.  Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor.

Authors:  Estella M Davis; Jon T Knezevich; Robyn M Teply
Journal:  Clin Pharmacol       Date:  2013-04-19

4.  Effects of ticagrelor in a mouse model of ischemic stroke.

Authors:  Keita Yamauchi; Takahiko Imai; Masamitsu Shimazawa; Toru Iwama; Hideaki Hara
Journal:  Sci Rep       Date:  2017-09-21       Impact factor: 4.379

5.  Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial.

Authors:  Kyungil Park; Young-Rak Cho; Jong-Sung Park; Tae-Ho Park; Moo-Hyun Kim; Young-Dae Kim
Journal:  J Cardiovasc Transl Res       Date:  2018-01-17       Impact factor: 4.132

6.  Ticagrelor and clopidogrel suppress NF-κB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells.

Authors:  Zhuyin Jia; Yiwei Huang; Xiaojun Ji; Jiaju Sun; Guosheng Fu
Journal:  BMC Cardiovasc Disord       Date:  2019-12-30       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.